Statin therapy is effective in primary and secondary prevention, but substantial residual risk remains on statin treatment, especially among high risk and very high risk patients. Add-on therapy with ezetimibe and proprotein convertase subtilisin /kexin type 9 (PCSK9) inhibitors provides additional risk reduction through further reduction in low density lipoprotein cholesterol. Elevated triglycerides/triglyceride rich lipoproteins contribute to atherogenesis and to the residual risk on statin therapy. Addition of icosapent ethyl to statins has recently been shown to markedly lower risk of ASCVD events in patients with established atherosclerotic CVD (ASCVD) and high risk patients with type II diabetes mellitus. These data are discussed in the context of current guidelines and synthesized in a decision pathway to guide combination lipid-lowering therapy in patients at high ASCVD risk.

中文翻译：

---

REDUCE IT 在临床实践中的意义。

他汀类药物治疗在一级和二级预防中是有效的，但他汀类药物治疗仍然存在大量残留风险，尤其是在高危和极高危患者中。依折麦布和前蛋白转化酶枯草杆菌蛋白酶 / kexin 9 型 (PCSK9) 抑制剂的附加治疗通过进一步降低低密度脂蛋白胆固醇提供额外的风险降低。升高的甘油三酯/富含甘油三酯的脂蛋白会导致动脉粥样硬化和他汀类药物治疗的残留风险。最近表明，在他汀类药物中加入 icosapentethyl 可显着降低已确诊的动脉粥样硬化 CVD (ASCVD) 和 II 型糖尿病高危患者的 ASCVD 事件风险。